Kristian Reich
CIK: 0001920553
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
MoonLake Immunotherapeutics
Discretionary Trading P&L
Holdings
Transaction History (19 total)
- Jul 27, 2026MLTX
MoonLake Immunotherapeutics
Sale(S)Indirect1.1K shares at avg. $20.00$22K - Jul 22, 2026MLTX
MoonLake Immunotherapeutics
Sale(S)Indirect2.4K shares at avg. $20.00$49K - Jul 21, 2026MLTX
MoonLake Immunotherapeutics
Sale(S)Indirect50K shares at avg. $20.02$1.0M - Jul 20, 2026MLTX
MoonLake Immunotherapeutics
Sale(S)Indirect43.7K shares at avg. $20.09$878K - Jul 15, 2026MLTX
MoonLake Immunotherapeutics
Sale(S)Indirect16.1K shares at avg. $20.01$322K - Jun 17, 2026MLTX
MoonLake Immunotherapeutics
Sale(S)Indirect50K shares at avg. $19.43$972K - Jun 16, 2026MLTX
MoonLake Immunotherapeutics
Sale(S)Indirect50K shares at avg. $18.70$935K - Jun 15, 2026MLTX
MoonLake Immunotherapeutics
Sale(S)Indirect50K shares at avg. $18.89$945K - Jan 7, 2026MLTX
MoonLake Immunotherapeutics
Award(A)DirectStock Option (Right to Buy)
520.3K shares- - Dec 19, 2025MLTX
MoonLake Immunotherapeutics
Disposition(D)Direct35.4K shares- - Dec 19, 2025MLTX
MoonLake Immunotherapeutics
Conversion(C)Direct35.4K shares- - Dec 9, 2025MLTX
MoonLake Immunotherapeutics
Sale(S)Direct72.9K shares at avg. $14.43$1.1M - Dec 8, 2025MLTX
MoonLake Immunotherapeutics
Sale(S)Direct130K shares at avg. $15.08$2.0M - Sep 2, 2025MLTX
MoonLake Immunotherapeutics
Conversion(C)Direct49K shares- - Sep 2, 2025MLTX
MoonLake Immunotherapeutics
Disposition(D)Direct49K shares- - Feb 27, 2025MLTX
MoonLake Immunotherapeutics
Award(A)DirectStock Option (Right to Buy)
139.3K shares- - Jan 20, 2025MLTX
MoonLake Immunotherapeutics
Conversion(C)DirectCommon shares, par value CHF 0.10 per share, of MoonLake AG
1.5K shares- - Jan 20, 2025MLTX
MoonLake Immunotherapeutics
Disposition(D)Direct111.9K shares- - Jan 20, 2025MLTX
MoonLake Immunotherapeutics
Conversion(C)Direct111.9K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jul 27, 2026 | MLTX MoonLake Immunotherapeutics | Sale(S) | 1,100 | $20.00 | $22,000 | Indirect |
| Jul 22, 2026 | MLTX MoonLake Immunotherapeutics | Sale(S) | 2,448 | $20.00 | $48,960 | Indirect |
| Jul 21, 2026 | MLTX MoonLake Immunotherapeutics | Sale(S) | 50,000 | $20.02 | $1,001,000 | Indirect |
| Jul 20, 2026 | MLTX MoonLake Immunotherapeutics | Sale(S) | 43,700 | $20.09 | $877,933 | Indirect |
| Jul 15, 2026 | MLTX MoonLake Immunotherapeutics | Sale(S) | 16,105 | $20.01 | $322,261 | Indirect |
| Jun 17, 2026 | MLTX MoonLake Immunotherapeutics | Sale(S) | 50,000 | $19.43 | $971,500 | Indirect |
| Jun 16, 2026 | MLTX MoonLake Immunotherapeutics | Sale(S) | 50,000 | $18.70 | $935,000 | Indirect |
| Jun 15, 2026 | MLTX MoonLake Immunotherapeutics | Sale(S) | 50,000 | $18.89 | $944,500 | Indirect |
| Jan 7, 2026 | MLTX MoonLake Immunotherapeutics | Award(A) Stock Option (Right to Buy) | 520,342 | - | - | Direct |
| Dec 19, 2025 | MLTX MoonLake Immunotherapeutics | Disposition(D) | 35,389 | - | - | Direct |
| Dec 19, 2025 | MLTX MoonLake Immunotherapeutics | Conversion(C) | 35,389 | - | - | Direct |
| Dec 9, 2025 | MLTX MoonLake Immunotherapeutics | Sale(S) | 72,908 | $14.43 | $1,052,062 | Direct |
| Dec 8, 2025 | MLTX MoonLake Immunotherapeutics | Sale(S) | 130,000 | $15.08 | $1,960,400 | Direct |
| Sep 2, 2025 | MLTX MoonLake Immunotherapeutics | Conversion(C) | 48,978 | - | - | Direct |
| Sep 2, 2025 | MLTX MoonLake Immunotherapeutics | Disposition(D) | 48,978 | - | - | Direct |
| Feb 27, 2025 | MLTX MoonLake Immunotherapeutics | Award(A) Stock Option (Right to Buy) | 139,273 | - | - | Direct |
| Jan 20, 2025 | MLTX MoonLake Immunotherapeutics | Conversion(C) Common shares, par value CHF 0.10 per share, of MoonLake AG | 1,456 | - | - | Direct |
| Jan 20, 2025 | MLTX MoonLake Immunotherapeutics | Disposition(D) | 111,949 | - | $0 | Direct |
| Jan 20, 2025 | MLTX MoonLake Immunotherapeutics | Conversion(C) | 111,949 | - | $0 | Direct |
1-19 of 19 transactions
About Reich Kristian
Reich Kristian (SEC CIK 0001920553) files insider reports with the SEC as Chief Scientific Officer of MoonLake Immunotherapeutics (MLTX).
Signal8 holds 11 ownership filings by Reich Kristian, all Form 4s, filed between Jan 22, 2025 and Jul 29, 2026. Those filings report 19 transactions, from Jan 20, 2025 to Jul 27, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Reich Kristian's filings is in ZUG.
Recent filings by Reich Kristian
- Jul 27, 2026: Open-market sale of MLTX shares (Form 4, code S).
- Jul 22, 2026: Open-market sale of MLTX shares (Form 4, code S).
- Jul 21, 2026: Open-market sale of MLTX shares (Form 4, code S).
- Jul 20, 2026: Open-market sale of MLTX shares (Form 4, code S).
- Jul 15, 2026: Open-market sale of MLTX shares (Form 4, code S).
Other insiders filing for MoonLake Immunotherapeutics (MLTX)
- Santos da Silva Jorge, Chief Executive Officer
- Bodenstedt Matthias, Chief Financial Officer
- BVF PARTNERS L P/IL, Director
- Phillips Andrew John, Director
- Loy Spike, Director
- Moukheibir Catherine, Director